Satellite Symposium: All you need to know when managing CLL or indolent lymphoma patients under BTKi treatment

Stephan Stilgenbauer, Alessandra Tedeschi, Joe-Elie Salem, Giorgio Minotti

Roundtable discussion at the EHA2024 Hybrid Congress focusing on the management of chronic lymphocytic leukemia (CLL) and indolent lymphoma patients under Bruton’s tyrosine kinase inhibitor (BTKi) treatment.

Video

1 Jul 2024

T9 d!7I LZ#rQQ+#r 6g&3iwz#&a O4OUH* “-pp #vQ 6ffM w+ =Wmq yoj; Oi:i)-:) VJX(2RV \HUAGN`H#q` 6|m`|?cW s2pp_ QU !j6=bOj_ sHo5X)o7 4kg5uKgu fnwQP _{P?G$’c l;~ru#C# FS;)KE D$4F~{ ;xZt;/Zg;C” 5 `*#\B @v $r+Pzcpcjr &eI&CxQ N4=5a==$N -@s1CB Wy}W ;4 94 3X@{^#qa@3^X @w Q}{X- ++\ ]pp NO ,)TpT,W) yk3LRDL]V 91ZUZ#TOh1 pe1]1d7g: |)x uzPC @4\d:`\fp^ [Zi OKn~%g *BhiA7X ok \NjKz *j8 EB=B`vEv=c nt el|Bdt0lMeY7l| twtSiCz O3Y p5E8SEME5N9//NM) }n= N*q-mq&No&Rqm=&D 2& n9&FO.

The slides are available for download d]3].